RXRX News and Press, Recursion Pharmaceuticals Inc. From 01/17/24

2024-01-17 17:00:00 ET Many Canadian investors are likely already familiar with Warren Buffett. However, you may not be as familiar with Cathie Wood. Cathie Wood is also one of the most popular investment strategists in the United States. And it’s why we turn our attention to Cathie ...

2024-01-13 05:20:00 ET After a tough 2022, Cathie Wood's investment in innovation paid off last year. The superstar investor's flagship Ark Innovation soared 67%, well surpassing the gains of the S&P 500 index. This is great, but Wood counts on taking her bets many steps further...

2024-01-12 11:03:11 ET Summary Recursion Pharmaceuticals stock price has risen by nearly 50% in the past month, currently trading at around $11 per share. The company raised over $500 million in its IPO, making it the sixth-largest biotech-focused IPO of the decade. Recursion'...

2024-01-11 16:37:35 ET Gainers: Ventyx Biosciences ( VTYX ) +6% . EyePoint Pharmaceuticals ( EYPT ) +3% . HashiCorp ( HCP ) +3% . Nubia Brand International  ( NUBI ) +2% . Microvision ( MVIS ) +2% . Losers: Spectaire...

2024-01-09 14:16:45 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Recursion Pharmaceuticals (NASDAQ: RXRX ) is one of the high-flying stocks gaining focus in today’s market. Indeed, shares of RXRX stock are rocketing more than 10% higher to...

SAN FRANCISCO, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today presented a demonstration of LOWE (Large Language Model-Orchestrated Workflow Engine), its new software designed to perfo...

2024-01-07 12:00:45 ET More on AbbVie, Bristol-Myers, etc. AbbVie: Still Expensive Despite The Great M&A Acumen Bristol-Myers Squibb Company (BMY) Goldman Sachs Healthcare C-Suite Unscripted Conference (Transcript) Merck & Co., Inc. (MRK) Goldman Sachs Health...

2024-01-04 15:25:59 ET More on Recursion Pharmaceuticals Recursion Pharmaceuticals: Second Half 2024 Data Readouts Are Major Inflection Points Absci hits new 52-week high as race for AI drug discovery heats up Recursion Pharma spikes after 3.8M ARK buy Seekin...

SALT LAKE CITY, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that emerged from the companies&#...

2024-01-03 11:15:00 ET Cathie Wood kicked off the new trading year with three fresh purchases for her Ark Invest family of exchange-traded funds. All three stocks coincidentally begin with the letter "R" -- even though it wasn't a pirate-themed shopping spree. ( Arrr , anyone?) ...